An innovative nanoparticle vaccine candidate for the Covid-19 virus produces virus-neutralizing antibodies in mice at levels 10X greater than is seen in people who have recovered from the infections, say researchers.

Designed by scientists at the University of Washington School of Medicine in Seattle, the vaccine candidate has been transferred to two companies for clinical development.